Agliati G, Lazzaroni M, Mariani G, Marras F, Massetto N, Menozzi C, Ortenzi E, Perna G, Puppo N, Santambrogio S
Abteilung für Innere Medizin, Krankenhaus von Vaprio, d'Adda, Mailand, Italien.
Arzneimittelforschung. 1992 Nov;42(11A):1414-6.
This double-blind study of dihydroergocristine (DHEC, CAS 17479-19-5) versus placebo was performed in 240 elderly patients affected by chronic cerebrovascular disease or organic brain syndrome. The therapy was carried on for one year. Results pointed out a decrease of SCAG total score and a significant improvement of the target items "confusion, mental alertness and memory performance" after DHEC versus placebo. Furthermore the data show that DHEC maintained its activity throughout the 12-month trial period. Very few and mild side-effects were reported for both groups, thus confirming the well known good safety of the compound. Based on results of this 1-year investigation, it is concluded that DHEC treatment should not be abruptly interrupted, but continued for as long as possible.
这项关于双氢麦角隐亭（DHEC，化学物质登记号17479-19-5）与安慰剂对比的双盲研究在240名患有慢性脑血管疾病或器质性脑综合征的老年患者中进行。治疗持续了一年。结果表明，与安慰剂相比，双氢麦角隐亭治疗后SCAG总分降低，且在“意识模糊、精神警觉性和记忆表现”等目标项目上有显著改善。此外，数据显示双氢麦角隐亭在整个12个月的试验期内均保持其活性。两组报告的副作用都很少且轻微，从而证实了该化合物众所周知的良好安全性。基于这项为期1年的调查结果，得出的结论是，双氢麦角隐亭治疗不应突然中断，而应尽可能长时间持续。
